Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575317 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL3192032 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6206953 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL98457 | 1.00 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL17816948 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL15143001 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL4124556 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6479731 | 0.85 | POLB (0.59) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL7158782 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 | |
| SCHEMBL6714428 | 0.83 | POLB (0.58) | POLBGAAALOX12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | claimed |
| WO-2020067683-A1 | NOVEL PROCESS FOR THE PREPARATION OF (+)-CIBENZOLINE SUCCINATE | CELLTRION INC. (KR) | 2020-04-02 | — | — | WO | claimed |
| US-20170233382-A1 | PROCESSES FOR THE PREPARATION OF A BACE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2017-08-17 | — | — | US | claimed |
| US-7161008-B2 | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | Sanofi - Aventis Deutschland GmbH (DE) | 2007-01-09 | — | — | US | claimed |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| US-RE38334-E1 | Diagnostics and therapeutics based on the roles of 3-PPI in intracellular signaling | NUTRIMED BIOTECH | 2003-11-25 | — | — | US | claimed |
| US-6020506-A | Synthesis of D-3 phosphorylated phosphoinositides and analogues | NUTRIMED BIOTECH (US) | 2000-02-01 | — | — | US | claimed |
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20260015355-A1 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-5385921-A | Treatment for neurodegeneration, alzheimer's disease, huntington's chorea; antihypoxic agents, antiischemic agents | AKTIEBOLAGET ASTRA (SE) | 1995-01-31 | — | — | US | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5231103-A | Lipoxygenase inhibitors as antiinflammatory agents, antiasthma and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| US-5091387-A | Spirocyclic oxytocin antagonists | MERCK & CO., INC. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0450761-A1 | Spirocyclic oxytocin antagonists | MERCK & CO. INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0444945-A2 | Use of spirocyclic compounds as oxytocin antagonists | MERCK & CO. INC. (US) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233382-A1 | PROCESSES FOR THE PREPARATION OF A BACE INHIBITOR | BACE2, BACE1, APP | POLB 1044/4885GAA 12/4885ALOX12 2536/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | POLB 704/4885GAA 1985/4885ALOX12 3987/4885 |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | ORMDL3, OR10J3, BCAT2 | POLB 3235/4885GAA 3204/4885ALOX12 1073/4885 |
| US-20260015355-A1 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | NR3C2, SRD5A1, SRD5A2 | POLB 1384/4885GAA 3212/4885ALOX12 2693/4885 |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | POLB 842/4885GAA 2623/4885ALOX12 4239/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | POLB 2046/4885GAA 1066/4885ALOX12 3784/4885 |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | POLB 842/4885GAA 2623/4885ALOX12 4239/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | POLB 1578/4885GAA 1808/4885ALOX12 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.